Survival following thrombolytic therapy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Myocardial infarction (MI) mortality studies have evaluated various thrombolytic drugs.
• Streptokinase, APSAC, and tissue plasminogen activator (t-PA) have demonstrated significant mortality reduction in MI.

Purpose of the Study:

• To review the efficacy of thrombolytic drugs in myocardial infarction.
• To identify optimal treatment timing and patient selection for thrombolytic therapy.

Main Methods:

• Analysis of major mortality studies on thrombolytic agents in MI.
• Comparison of different thrombolytic drugs, including streptokinase, APSAC, and t-PA.
• Evaluation of treatment outcomes based on symptom onset time and patient demographics.

Main Results:

• Streptokinase, APSAC, and t-PA significantly reduce mortality in myocardial infarction.
• Early administration of thrombolytic therapy is crucial for maximum benefit.
• Substantial benefits are observed in elderly patients and those treated 6-24 hours after symptom onset.

Conclusions:

• Thrombolytic therapy is effective in reducing MI mortality.
• Clinical practice should not rigidly adhere to study entry criteria, allowing broader patient access.
• Timely and inclusive application of thrombolytic drugs can improve patient outcomes.